RE: CEO31 Aug 2021 14:59
Certainly looks like no-one wants to commit to such a prediction.
I'm sceptical on this 'take-over talk', the market doesn't seem to be buying it, the company talk about licensing being an option post data returns.
As I mentioned to Kane the other week, there are two figures involved. The figure that individuals wish to see, and then the figure someone is willing to pay.
If you were a company CEO proposing to your board a bid for NFX, you would be positioning a bid easily sub 5p. No company board is going to sanction you proposing a bid 4 or 5 times (or higher) greater than the current market value. Yes, you may draw other bidders out of the woodwork, but you'd try to get success through as cheap as possible.
For a while I had been thinking Ebers and DT were playing a game here, with both DT and AC drip selling to put pressure on the sp, whilst Ebers are in the process of their RTO raising £25m. They would then buy up NFX for something in that zone.
That said there is also Senari Pharma who Anne Brindley works for who are currently raising £20m and are looking at the same pharma space.
Like others I would love a double figure share price, but NFX is very very exposed to low-ball offers down here with little or now defence.